查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012376

合成激素市場：依激素分類、技術、最終用戶和應用分類－2026-2032年全球市場預測

Synthetic Hormones Market by Hormone Class, Technology, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年合成荷爾蒙市值為11.7億美元，預計2026年將成長至13.3億美元，複合年成長率為14.88%，到2032年將達到31.1億美元。

主要市場統計數據
基準年 2025 11.7億美元
預計年份：2026年 13.3億美元
預測年份 2032 31.1億美元
複合年成長率 (%) 14.88%

對合成荷爾蒙市場進行權威概述，重點關注臨床因素、技術進步以及相關人員面臨的策略挑戰。

合成荷爾蒙市場正處於臨床需求、技術創新和不斷變化的監管環境的交匯點。近年來，隨著人們對安全性、給藥便利性和可負擔性的日益關注，工程胜肽及其類似物的研發速度加快。隨著遠端醫療的普及和居家照護的擴展，患者治療路徑也在不斷演變，製造商和醫療保健提供者必須平衡複雜的生產需求、嚴格的品管以及價格競爭的壓力。

對技術、法規和通路的整合如何重塑荷爾蒙療法的發展路徑和商業策略進行了引人入勝的分析。

過去十年間，變革性的改變徹底改變了合成荷爾蒙的研發、生產和給藥方式。重組DNA技術和細胞表現系統的創新拓展了可治療分子的範圍，從而提高了生物製藥的純度，並改善了批次間的性能一致性。同時，製劑科學和給藥裝置的進步降低了自我給藥的門檻，使荷爾蒙療法的應用範圍從傳統的臨床環境擴展到居家照護和遠端醫療模式。

詳細檢驗2025 年關稅措施對整個合成荷爾蒙價值鏈的影響，包括供應鏈重組、採購多元化和定價策略。

2025年累積關稅的實施對合成荷爾蒙生態系統的成本結構、供應商選擇和策略採購產生了重大影響。依賴跨境供應鏈的製造商面臨新的獎勵，需要重新評估其供應商組合，盡可能優先選擇在地採購，並重新談判長期合約以吸收或緩解關稅帶來的成本壓力。這些調整通常涉及重組籌資策略，優先選擇在優惠貿易區內營運的供應商，或探索近岸外包方案以降低進口關稅和物流波動風險。

將荷爾蒙分類、治療應用、底層技術和終端使用者管道與可操作的策略重點連結起來的綜合細分分析。

基於洞察的市場區隔能夠清楚揭示治療和商業性機會的交會點，以及營運風險集中的區域。根據荷爾蒙分類，市場研究涵蓋雌激素、胰島素和甲狀腺激素三大領域，每種荷爾蒙都有其獨特的臨床路徑和生產方法，需要相應的監管策略和管理方法。根據應用領域，市場研究涵蓋避孕、糖尿病、生長激素缺乏症、更年期症狀和甲狀腺疾病。在此維度下，避孕進一步細分為複方口服避孕藥和僅含孕激素的避孕藥；生長激素缺乏症細分為成人生長激素缺乏症和兒童生長激素缺乏症；更年期症狀細分為潮熱、骨質疏鬆症和陰道萎縮；甲狀腺疾病細分為甲亢和甲狀腺機能低下症，從而能夠更精準地定位臨床適應症和患者群體。

針對美洲、歐洲、中東和非洲以及亞太地區的法規、生產能力和商業性活動，存在區域性影響。

區域趨勢反映了獨特的監管、生產和商業性特徵，這些特徵會影響策略選擇。在美洲，先進的臨床生態系統和對胰島素及避孕藥的強勁需求與集中的製造群並存，這些集群優先考慮生物製藥規模化生產和先進製劑技術。在歐洲、中東和非洲，監管機構正日益協調生物相似藥的核准流程，而醫療保健系統則優先考慮成本控制和可及性，這促使製造商完善其價值論證，並更深入地參與區域衛生技術評估流程。在亞太地區，重組技術的快速普及，以及現有和新興製造地產能的提升，加上不斷成長的公共和私人醫療保健支出，正在契約製造和本地夥伴關係創造競爭壓力和合作機會。

決定荷爾蒙治療領域生產能力、技術差異化和商業化效果的關鍵競爭對手和合作夥伴策略。

合成荷爾蒙領域的競爭格局由跨國製藥公司、專業生物技術公司、合約研發生產機構（CDMO）以及專注於新型遞送平台的創新企業所組成。領先的生物製藥研發公司正利用其在重組技術和先進細胞表達系統的投資，擴大其在胰島素類似物和生長激素荷爾蒙療法領域的市場佔有率。同時，傳統的小分子藥物生產商也不斷改進其胜肽和類固醇激素的化學合成路線。

為領導者提供有針對性、可操作的建議，以增強韌性、加速商業化，並使發展適應不斷變化的醫療保健服務模式。

產業領導者應採取一系列優先且切實可行的措施，以增強韌性並加速價值創造。首先，透過選擇能夠平衡臨床差異化和服務交付成本的研發路徑，並在產品生命週期早期檢驗可擴展的生產路線，使研發重點與供應和生產的可行性保持一致。其次，實現原料和中間體來源多元化，並建立緊急供應合約和雙重採購安排，以降低政策主導的關稅和物流瓶頸帶來的風險。第三，投資於監管策略和上市後證據的收集，以解決生物類似性問題、長期安全性問題以及區域報銷要求。這些努力應包括與監管機構和衛生技術評估機構積極合作，以促進市場進入。

嚴謹、多方面的調查方法，結合與主要相關人員的對話、監管和專利分析以及三角驗證的二手證據，確保了可靠的見解。

本調查方法結合了一手資料和二手資料，以確保獲得可靠且多方驗證的見解。一手資料包括對整個價值鏈上的相關人員進行結構化訪談和深入討論，這些利害關係人包括研發經理、生產經理、法規專家、銷售主管、臨床研究人員和支付者。除這些定性資訊外，本研究還對監管指南、臨床試驗註冊資訊、專利趨勢和公開的監管文件進行了系統性的文獻分析，以了解各方對近期先例和證據的預期。

為合成荷爾蒙領域的相關人員提供簡潔而前瞻性的結論，整合了策略挑戰、營運風險和機會途徑。

總而言之，合成激素領域正處於一個轉折點，科學技術能力、監管進步和不斷變化的醫療模式在此交匯融合。重組DNA技術的進步和化學合成路線的改進正在開闢新的治療選擇，並實現以患者為中心的給藥方法。然而，複雜的生產要求、不斷變化的監管預期以及政策驅動的供應鏈壓力正在抵消這些機會。積極將證據生成、監管合作和供應鏈韌性納入策略規劃的相關人員，將更有能力將創新轉化為擴充性且經濟高效的患者解決方案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依荷爾蒙類型分類的合成荷爾蒙市場

  • 雌激素
  • 胰島素
  • 甲狀腺

第9章：合成荷爾蒙市場：依技術分類

  • 化學合成
    • 液相合成
    • 固相合成
  • 重組DNA技術
    • 細菌表現系統
    • 哺乳動物細胞表現系統
    • 酵母表現系統

第10章 合成荷爾蒙市場：依最終用戶分類

  • 診所
    • 全科診所
    • 專科診所
  • 居家醫療
    • 護理服務
    • 自我管理
  • 醫院
    • 私立醫院
    • 公立醫院
  • 網路藥房
    • 非處方藥
    • 處方箋藥
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第11章：合成荷爾蒙市場：依應用領域分類

  • 避孕
    • 口服避孕藥
    • 僅含黃體素的避孕藥
  • 糖尿病
  • 生長激素缺乏症
    • 成人生長激素缺乏症
    • 兒童生長激素缺乏症
  • 更年期症狀
    • 潮熱
    • 骨質疏鬆症
    • 陰道萎縮
  • 甲狀腺疾病
    • 甲狀腺功能亢進
    • 甲狀腺機能低下症

第12章 合成荷爾蒙市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：合成荷爾蒙市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 合成荷爾蒙市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國合成荷爾蒙市場

第16章：中國合成荷爾蒙市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • Endo Pharmaceuticals Inc.
  • Ferring BV
  • Gilead Sciences Inc.
  • IBSA Institut Biochimique SA
  • Ipsen SA
  • Johnson & Johnson
  • Lupin Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Organon & Co.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Theramex
  • TherapeuticsMD Inc.
  • Viatris Inc.
Product Code: MRR-431C35F6C25D

The Synthetic Hormones Market was valued at USD 1.17 billion in 2025 and is projected to grow to USD 1.33 billion in 2026, with a CAGR of 14.88%, reaching USD 3.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.17 billion
Estimated Year [2026] USD 1.33 billion
Forecast Year [2032] USD 3.11 billion
CAGR (%) 14.88%

An authoritative overview of the synthetic hormones landscape highlighting clinical drivers, technological advances, and strategic imperatives for industry stakeholders

The synthetic hormones landscape sits at the intersection of clinical need, technological innovation, and shifting regulatory frameworks. Recent years have witnessed accelerated development of engineered peptides and analogs alongside renewed emphasis on safety, delivery convenience, and affordability. As patient pathways evolve through expanded telehealth adoption and greater home-based care, manufacturers and healthcare providers must reconcile complex production demands with stringent quality controls and competitive pricing pressures.

Translational progress in recombinant DNA techniques and refined chemical synthesis has enabled a broader therapeutic palette, but it also introduces new manufacturing dependencies and regulatory touchpoints. Concurrently, clinical practice patterns for contraception, diabetes, growth hormone deficiency, menopausal care, and thyroid disorders are being reshaped by demographic trends, evolving clinical guidelines, and patient preferences for less invasive administration. These dynamics require stakeholders to rethink portfolio strategies, manufacturing footprints, and channel engagement models.

Strategic clarity is now essential for organizations that seek to convert scientific advances into durable commercial outcomes. This report distills the most consequential shifts, identifies segmentation-driven implications, and offers actionable recommendations to navigate operational risks while capturing momentum from scientific and market developments.

Compelling analysis of converging technological, regulatory, and channel shifts that are reshaping development pathways and commercial strategies for hormone therapies

The past decade has brought transformative shifts that are redefining how synthetic hormones are developed, manufactured, and delivered. Innovations in recombinant DNA methods and cell expression systems have expanded the feasible range of therapeutic molecules, enabling higher purity biologics and more consistent batch-to-batch performance. At the same time, advances in formulation science and delivery devices have reduced barriers to self-administration, thereby extending the reach of hormone therapies beyond traditional clinical settings into homecare and telemedicine-facilitated models.

Regulatory regimes are becoming more nuanced, with agencies intensifying scrutiny on comparator strategies for biosimilars and on pharmacovigilance for long-term hormone use. This regulatory tightening is fostering greater emphasis on clinical evidence generation and post-market safety surveillance, which in turn influences development timelines and commercial positioning. Concurrently, supply chain resilience has moved to the forefront, with manufacturers seeking geographic diversification of raw material suppliers and investing in redundant manufacturing capacities to mitigate geopolitical and logistic disruptions.

Market channels are also shifting: digital pharmacies and prescription-based online dispensing platforms are altering patient acquisition and adherence patterns, while specialty clinics and integrated care providers are experimenting with subscription models and bundled care pathways. Taken together, these shifts demand that industry participants align R&D, regulatory strategy, manufacturing investments, and commercial models to sustain growth and manage emerging risks.

In-depth examination of how 2025 tariff measures have compelled supply chain reconfiguration, sourcing diversification, and pricing strategies across the synthetic hormones value chain

The implementation of cumulative tariffs in 2025 has had material implications for cost structures, supplier selection, and strategic sourcing within the synthetic hormones ecosystem. Manufacturers that rely on cross-border supply chains faced renewed incentives to reassess their vendor portfolios, prioritize local content where feasible, and renegotiate long-term agreements to absorb or mitigate tariff-related cost pressures. These adjustments often entailed reconfiguring procurement strategies to favor suppliers operating within preferential trade zones or exploring nearshoring options to reduce exposure to import duties and logistical volatility.

Pharmaceutical companies also had to weigh the operational trade-offs between relocating certain production steps and maintaining continuity of supply. For some, re-shoring advanced manufacturing processes proved capital intensive but strategically justified to secure critical intermediates and biologics output. For others, investing in dual-sourcing frameworks and inventory buffering provided a more flexible response to tariff volatility. In parallel, payers and distributors scrutinized price and reimbursement dynamics more closely, prompting some manufacturers to accelerate cost-efficiency programs and to pursue value demonstrations that emphasize total cost of care rather than unit price alone.

Overall, the tariff environment highlighted the need for integrated commercial and supply chain strategies that can withstand policy-driven shocks while preserving access and quality of hormone therapies across diverse care settings.

Comprehensive segmentation analysis that links hormone classes, therapeutic applications, enabling technologies, and end-user channels to actionable strategic priorities

Insight-driven segmentation clarifies where therapeutic and commercial opportunities converge and where operational risks concentrate. Based on hormone class, the market is studied across Estrogen, Insulin, and Thyroid, each representing distinct clinical pathways and manufacturing modalities that require tailored regulatory strategies and delivery approaches. Based on application, the market is studied across Contraception, Diabetes, Growth Hormone Deficiency, Menopausal Symptoms, and Thyroid Disorders; within this dimension, Contraception is further studied across Combined Oral Contraceptive and Progestin Only Contraceptive, Growth Hormone Deficiency is further studied across Adult GHD and Pediatric GHD, Menopausal Symptoms is further studied across Hot Flashes, Osteoporosis, and Vaginal Atrophy, and Thyroid Disorders is further studied across Hyperthyroidism and Hypothyroidism, enabling fine-grained targeting of clinical indications and patient segments.

Based on technology, the market is studied across Chemical Synthesis and Recombinant DNA Technology; the Chemical Synthesis pathway is further studied across Liquid-Phase Synthesis and Solid-Phase Synthesis while the Recombinant DNA Technology pathway is further studied across Bacterial Expression Systems, Mammalian Cell Expression Systems, and Yeast Expression Systems, highlighting trade-offs between yield, post-translational modification fidelity, and cost of goods. Based on end user, the market is studied across Clinics, Homecare Settings, Hospitals, Online Pharmacies, and Retail Pharmacies; within that classification the Clinics category is further disaggregated into General Practice Clinics and Specialty Clinics, Homecare Settings into Nursing Service and Self-Administration, Hospitals into Private Hospitals and Public Hospitals, Online Pharmacies into Over-The-Counter and Prescription-Based models, and Retail Pharmacies into Chain Pharmacies and Independent Pharmacies, which clarifies distribution pathways, reimbursement touchpoints, and patient access considerations.

These segmentation lenses collectively enable stakeholders to prioritize investments, design differentiated clinical evidence strategies, and align manufacturing footprints with the specific demands of each therapeutic and channel combination.

Region-specific implications for regulation, manufacturing capacity, and commercial engagement across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics present distinctive regulatory, manufacturing, and commercial contours that influence strategic choices. In the Americas, advanced clinical ecosystems and strong insulin and contraceptive demand coexist with concentrated manufacturing clusters that prioritize biologics scale-up and advanced formulation capabilities. In Europe, Middle East & Africa, regulators increasingly harmonize biosimilar pathways while healthcare systems emphasize cost containment and access, prompting manufacturers to refine value dossiers and engage more deeply with regional health technology assessment processes. In Asia-Pacific, rapid adoption of recombinant technologies and growing capacity in both established and emerging manufacturing hubs are complemented by expanding private and public healthcare spending, creating competitive pressure and collaborative opportunities for contract manufacturing and local partnerships.

Across these regions, differences in reimbursement paradigms, clinical practice patterns, and supply chain resilience require tailored market entry and growth strategies. Regulatory alignment initiatives and regional trade agreements can create avenues for streamlined approvals and cross-border clinical collaboration, but local manufacturing capabilities and distribution networks remain decisive factors for ensuring timely patient access. Consequently, companies that develop region-specific pathways for evidence generation, regulatory engagement, and channel management are better positioned to convert scientific strengths into sustained commercial performance.

Critical competitive dynamics and partnership strategies that determine capacity, technological differentiation, and commercialization effectiveness in the hormone therapeutics sector

Competitive dynamics in synthetic hormones are shaped by a mix of multinational pharmaceutical corporations, specialized biotechnology firms, contract development and manufacturing organizations, and emerging innovators focused on novel delivery platforms. Leading biologics developers have leveraged investments in recombinant technologies and advanced cell expression systems to extend their presence across insulin analogs and growth hormone therapies, while traditional small-molecule manufacturers continue to refine chemical synthesis routes for peptide and steroid-based hormones.

Strategic collaboration between originators and contract manufacturers has intensified as companies seek modular capacity and flexible supply arrangements. Partnerships with technology providers that specialize in high-yield bacterial and mammalian expression systems, as well as firms that offer advanced formulation and device integration, are increasingly important for accelerating time to clinic and ensuring scalable production. Mergers and acquisitions activity concentrates on filling capability gaps, securing geographic manufacturing footprint, and acquiring differentiated delivery technologies that enhance patient adherence. The competitive landscape rewards organizations that combine scientific differentiation with operational excellence, evidenced by investments in regulatory compliance, quality management systems, and integrated data platforms that support lifecycle evidence generation.

Targeted and practical recommendations for leaders to strengthen resilience, accelerate commercialization, and align development with evolving care delivery models

Industry leaders should pursue a set of prioritized, actionable measures to strengthen resilience and accelerate value creation. First, align R&D priorities with delivery and manufacturing feasibility by selecting development pathways that balance clinical differentiation with cost-to-serve considerations, and by validating scalable production routes early in the lifecycle. Second, diversify sourcing across raw materials and intermediates and build contingency supply agreements or dual-sourcing arrangements to reduce vulnerability to policy-driven tariffs and logistic bottlenecks. Third, invest in regulatory strategy and post-market evidence generation to address biosimilarity concerns, long-term safety questions, and regional reimbursement requirements. These efforts should include proactive engagement with regulators and health technology assessment bodies to streamline market access.

Fourth, redesign commercial models to reflect evolving patient pathways by supporting homecare and self-administration programs, enabling remote monitoring, and leveraging prescription-based online channels to enhance adherence and reach underserved populations. Fifth, pursue strategic collaborations with contract manufacturers and technology partners to access specialized expression systems, formulation expertise, and device integration capabilities without the need for heavy capital outlays. Lastly, embed advanced analytics and quality-by-design principles across development and manufacturing to improve yield, reduce batch failures, and accelerate time-to-clinic. Executed together, these actions will enable companies to mitigate near-term disruptions while building differentiated, sustainable advantage.

Rigorous multi-method methodology combining primary stakeholder engagement, regulatory and patent analysis, and triangulated secondary evidence to ensure robust insights

The research methodology combines primary and secondary approaches to ensure robust, triangulated insights. Primary research encompassed structured interviews and in-depth discussions with stakeholders across the value chain including R&D leads, manufacturing heads, regulatory affairs specialists, commercial executives, clinical investigators, and payers. This qualitative input was complemented by systematic document analysis of regulatory guidance, clinical trial registries, patent landscapes, and publicly disclosed regulatory submissions to understand recent precedent and evidentiary expectations.

Secondary research drew on peer-reviewed literature, conference proceedings, technology white papers, and company disclosures to map technological trajectories and historical performance trends. Data synthesis followed a transparent triangulation process that reconciled divergent perspectives and tested hypotheses against multiple independent sources. Where appropriate, scenario analyses were used to examine the operational implications of supply chain disruptions, tariff changes, and regulatory shifts. Quality controls included cross-validation of interview findings, methodological audits, and review by domain experts to ensure the integrity and relevance of the conclusions presented.

Concise and forward-looking conclusion synthesizing strategic imperatives, operational risks, and opportunity pathways for synthetic hormone stakeholders

In summary, the synthetic hormones sector is at an inflection point where scientific capability, regulatory evolution, and shifting care models intersect. Advances in recombinant DNA technologies and improved chemical synthesis routes are unlocking new therapeutic options and enabling more patient-centric delivery modalities, yet these opportunities are counterbalanced by complex manufacturing requirements, evolving regulatory expectations, and policy-induced supply chain pressures. Stakeholders that proactively integrate evidence generation, regulatory engagement, and supply chain resilience into their strategic planning will be better equipped to translate innovation into scalable, cost-effective patient solutions.

Moving forward, success will depend on pragmatic alignment across R&D, manufacturing, and commercial functions, coupled with targeted partnerships that bring specialized capabilities without excessive capital commitments. By emphasizing flexible sourcing, robust quality systems, and patient-oriented distribution channels, organizations can navigate near-term disruptions while positioning themselves to capture long-term clinical and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Synthetic Hormones Market, by Hormone Class

  • 8.1. Estrogen
  • 8.2. Insulin
  • 8.3. Thyroid

9. Synthetic Hormones Market, by Technology

  • 9.1. Chemical Synthesis
    • 9.1.1. Liquid-Phase Synthesis
    • 9.1.2. Solid-Phase Synthesis
  • 9.2. Recombinant Dna Technology
    • 9.2.1. Bacterial Expression Systems
    • 9.2.2. Mammalian Cell Expression Systems
    • 9.2.3. Yeast Expression Systems

10. Synthetic Hormones Market, by End User

  • 10.1. Clinics
    • 10.1.1. General Practice Clinics
    • 10.1.2. Specialty Clinics
  • 10.2. Homecare Settings
    • 10.2.1. Nursing Service
    • 10.2.2. Self-Administration
  • 10.3. Hospitals
    • 10.3.1. Private Hospitals
    • 10.3.2. Public Hospitals
  • 10.4. Online Pharmacies
    • 10.4.1. Over-The-Counter
    • 10.4.2. Prescription-Based
  • 10.5. Retail Pharmacies
    • 10.5.1. Chain Pharmacies
    • 10.5.2. Independent Pharmacies

11. Synthetic Hormones Market, by Application

  • 11.1. Contraception
    • 11.1.1. Combined Oral Contraceptive
    • 11.1.2. Progestin Only Contraceptive
  • 11.2. Diabetes
  • 11.3. Growth Hormone Deficiency
    • 11.3.1. Adult GHD
    • 11.3.2. Pediatric GHD
  • 11.4. Menopausal Symptoms
    • 11.4.1. Hot Flashes
    • 11.4.2. Osteoporosis
    • 11.4.3. Vaginal Atrophy
  • 11.5. Thyroid Disorders
    • 11.5.1. Hyperthyroidism
    • 11.5.2. Hypothyroidism

12. Synthetic Hormones Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Synthetic Hormones Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Synthetic Hormones Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Synthetic Hormones Market

16. China Synthetic Hormones Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Amgen Inc.
  • 17.8. AstraZeneca PLC
  • 17.9. Bayer AG
  • 17.10. Eli Lilly and Company
  • 17.11. Endo Pharmaceuticals Inc.
  • 17.12. Ferring B.V.
  • 17.13. Gilead Sciences Inc.
  • 17.14. IBSA Institut Biochimique SA
  • 17.15. Ipsen S.A.
  • 17.16. Johnson & Johnson
  • 17.17. Lupin Pharmaceuticals Inc.
  • 17.18. Merck & Co. Inc.
  • 17.19. Merck KGaA
  • 17.20. Novartis AG
  • 17.21. Novo Nordisk A/S
  • 17.22. Organon & Co.
  • 17.23. Pfizer Inc.
  • 17.24. Sanofi SA
  • 17.25. Teva Pharmaceutical Industries Ltd.
  • 17.26. Theramex
  • 17.27. TherapeuticsMD Inc.
  • 17.28. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SYNTHETIC HORMONES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SYNTHETIC HORMONES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SYNTHETIC HORMONES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SYNTHETIC HORMONES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SYNTHETIC HORMONES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SYNTHETIC HORMONES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 280. GCC SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 281. GCC SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2032 (USD MILLION)
  • TABLE 282. GCC SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. GCC SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 284. GCC SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. GCC SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. GCC SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 287. GCC SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 288. GCC SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 289. GCC SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 290. GCC SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 291. GCC SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. GCC SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2032 (USD MILLION)
  • TABLE 293. GCC SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 294. GCC SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2032 (USD MILLION)
  • TABLE 295. GCC SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMP